You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Abbvie Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Abbvie
International Patents:2972
US Patents:234
Tradenames:131
Ingredients:105
NDAs:145
Drug Master File Entries: 1
Patent Litigation for Abbvie: See patent lawsuits for Abbvie

Drugs and US Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-001 Sep 17, 2015 RX Yes Yes RE47350 ⤷  Try for Free ⤷  Try for Free
Abbvie VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 AB RX Yes Yes 9,700,542 ⤷  Try for Free Y ⤷  Try for Free
Abbvie NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-004 Jul 18, 2016 AB RX Yes No 8,283,379*PED ⤷  Try for Free Y ⤷  Try for Free
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-003 Jul 28, 1997 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Abbvie RINVOQ upadacitinib TABLET, EXTENDED RELEASE;ORAL 211675-003 Mar 16, 2022 RX Yes Yes 11,198,697 ⤷  Try for Free Y ⤷  Try for Free
Abbvie RINVOQ upadacitinib TABLET, EXTENDED RELEASE;ORAL 211675-002 Jan 14, 2022 RX Yes No 10,730,883 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-005 Jan 21, 1994 6,036,976 ⤷  Try for Free
Abbvie ORILISSA elagolix sodium TABLET;ORAL 210450-002 Jul 23, 2018 6,872,728 ⤷  Try for Free
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-003 Jul 28, 1997 6,080,428 ⤷  Try for Free
Abbvie ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-004 Apr 5, 2002 5,164,190 ⤷  Try for Free
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-001 May 26, 2005 5,587,497*PED ⤷  Try for Free
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-001 May 26, 2005 5,597,815*PED ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ABBVIE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 10 mg and 20 mg ➤ Subscribe 2005-03-30
➤ Subscribe Extended-release Capsules 28 mg ➤ Subscribe 2013-06-12
➤ Subscribe Injection 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial ➤ Subscribe 2009-08-04
➤ Subscribe Tablets 145 mg ➤ Subscribe 2007-10-19
➤ Subscribe Suppository 1000 mg ➤ Subscribe 2013-05-24
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 2013-06-10
➤ Subscribe Injection 400 mg/vial and 600 mg/vial ➤ Subscribe 2014-10-29
➤ Subscribe Tablets 5 mg/200 mg ➤ Subscribe 2005-05-27
➤ Subscribe Extended-release Tablet 500 mg ➤ Subscribe 2010-12-06
➤ Subscribe Capsules 21 mg/10 mg ➤ Subscribe 2016-09-23
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-23
➤ Subscribe Extended-release Tablets 500 mg ➤ Subscribe 2005-02-08
➤ Subscribe Tablets 100 mg/25 mg ➤ Subscribe 2008-12-23
➤ Subscribe Ophthalmic Solution 0.10% ➤ Subscribe 2006-12-20
➤ Subscribe Extended-release Tablets 2 mg/180 mg and 2 mg/240 mg ➤ Subscribe 2007-11-09
➤ Subscribe Capsules 145 mcg and 290 mcg ➤ Subscribe 2016-08-30
➤ Subscribe Ophthalmic Solution 0.2%/0.5% ➤ Subscribe 2008-11-21
➤ Subscribe Extended-release Tablets 4 mg/ 240 mg ➤ Subscribe 2007-07-24
➤ Subscribe Capsules 100 mg ➤ Subscribe 2012-10-31
➤ Subscribe Ophthalmic Solution 0.03% ➤ Subscribe 2008-12-22
➤ Subscribe Delayed-release Capsules 400 mg ➤ Subscribe 2014-06-17
➤ Subscribe Tablets 1 mg, 2 mg and 4 mg ➤ Subscribe 2004-10-04
➤ Subscribe Injection 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials ➤ Subscribe 2008-11-28
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2010-12-07
➤ Subscribe Delayed-release Capsules 135 mg ➤ Subscribe 2009-09-01
➤ Subscribe Tablets 12.5 mg, 25 mg, 50 mg, and 100 mg ➤ Subscribe 2013-01-14
➤ Subscribe Capsules 4 mcg ➤ Subscribe 2008-08-25
➤ Subscribe Capsules 5 mg ➤ Subscribe 2005-08-17
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 2013-08-16
➤ Subscribe Gel 10% ➤ Subscribe 2014-06-19
➤ Subscribe Tablets 48 mg ➤ Subscribe 2008-07-01
➤ Subscribe Injection 10 mg/mL (2 mL) ➤ Subscribe 2018-07-13
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg ➤ Subscribe 2013-06-17
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 2009-08-12
➤ Subscribe Tablets 2.5 mg/200 mg ➤ Subscribe 2006-02-24
➤ Subscribe Delayed-release Tablets 800 mg ➤ Subscribe 2011-07-13
➤ Subscribe Capsules 14 mg/10 mg and 28 mg/10 mg ➤ Subscribe 2015-05-18
➤ Subscribe Ophthalmic Solution 0.40% ➤ Subscribe 2005-01-28
➤ Subscribe Tablets 10 mg, 20 mg, and 40 mg ➤ Subscribe 2015-01-21
➤ Subscribe Extended-release Tablets 250 mg ➤ Subscribe 2004-05-03
➤ Subscribe Capsules 7 mg/10 mg ➤ Subscribe 2016-09-26
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-24
➤ Subscribe Extended-release Tablets 7.5 mg and 15 mg ➤ Subscribe 2008-12-22
➤ Subscribe Oral Solution 80 mg/20 mg per mL ➤ Subscribe 2014-06-19
➤ Subscribe Ophthalmic Solution 0.15% ➤ Subscribe 2006-11-03
➤ Subscribe Extended-release Tablets 1 mg/240 mg ➤ Subscribe 2008-02-20
➤ Subscribe Tablets 100 mg ➤ Subscribe 2010-12-21
➤ Subscribe Ophthalmic Solution 0.25% ➤ Subscribe 2014-07-30
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 2017-06-09
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 2012-10-09
➤ Subscribe Ophthalmic Solution 0.01% ➤ Subscribe 2011-04-05
➤ Subscribe Delayed-release Capsules 45 mg ➤ Subscribe 2009-09-02
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2007-10-16
➤ Subscribe Capsules 1 mcg and 2 mcg ➤ Subscribe 2008-10-14
➤ Subscribe Topical Solution 0.03% ➤ Subscribe 2010-05-03
➤ Subscribe Extended-release Capsules 20 mg, 40 mg, 80 mg and 120 mg ➤ Subscribe 2017-07-25
➤ Subscribe Tablets 400 mg and 600 mg ➤ Subscribe 2010-05-10
➤ Subscribe Gel 7.5% ➤ Subscribe 2017-02-13

Supplementary Protection Certificates for Abbvie Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1259550 08C0052 France ⤷  Try for Free PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
1043327 C300568 Netherlands ⤷  Try for Free PRODUCT NAME: CEFTAROLINE FOSAMIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/12/785/001 00120823
2368890 SPC/GB15/015 United Kingdom ⤷  Try for Free PRODUCT NAME: OMBITASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/14/982 20150119
1663996 SPC/GB17/059 United Kingdom ⤷  Try for Free PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING CARIPRAZINE HYDROCHLORIDE; REGISTERED: UK EU/1/17/1209/001-040 20170717; UK PLGB 04854/0173 20170717; UK PLGB 04854/0174 20170717; UK PLGB 04854/0175 20170717; UK PLGB 04854/0176 20170717
2435432 2017/023 Ireland ⤷  Try for Free PRODUCT NAME: VENETOCLAX (VENCLYXTO); REGISTRATION NO/DATE: EU/1/16/1138 20161205
0136011 2000C/027 Belgium ⤷  Try for Free PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Abbvie – Market Position, Strengths & Strategic Insights

Last updated: July 12, 2025

Introduction

AbbVie, a global biopharmaceutical leader spun off from Abbott Laboratories in 2013, commands a formidable presence in the pharmaceutical industry. As a key player in immunology, oncology, and neuroscience, the company navigates a highly competitive landscape marked by rapid innovation, patent expirations, and strategic acquisitions. This analysis examines AbbVie's current market position, core strengths, and forward-looking strategies, drawing on publicly available data to inform business decisions in an era of escalating healthcare demands.

AbbVie's Market Position

AbbVie's standing in the pharmaceutical sector reflects its dominance in high-value therapeutic areas, particularly autoimmune diseases and cancer treatments. In 2023, the company reported global revenues exceeding $54 billion, with Humira—its blockbuster anti-inflammatory drug—accounting for a significant portion until its patent expiration in major markets. Despite this challenge, AbbVie maintains a top-tier market position, ranking among the world's top 10 pharmaceutical firms by market capitalization, currently valued at over $300 billion.

The company's market share in immunology stands out, where it holds approximately 20% of the global market for biologic therapies, according to recent industry reports. Competitors like Johnson & Johnson and Pfizer pressure this space, but AbbVie's diversified portfolio, including newer drugs like Skyrizi and Rinvoq, has helped sustain its edge. In oncology, AbbVie collaborates with partners such as Roche to advance treatments, securing a foothold in a market projected to reach $500 billion by 2030.

Geographically, AbbVie leads in North America, capturing about 45% of its revenue from the U.S., where regulatory approvals from the FDA have been swift. Emerging markets in Asia-Pacific and Europe present growth opportunities, though pricing pressures and biosimilar competition erode margins. For instance, Humira faced biosimilar entrants in Europe by 2018, reducing AbbVie's share by roughly 10% in that region. This dynamic underscores the need for AbbVie to innovate beyond legacy products, as rivals like Novartis and Merck intensify their pipelines.

Strengths of AbbVie

AbbVie's strengths lie in its robust intellectual property portfolio, innovative research capabilities, and strategic financial discipline. At the core is its patent strategy, which has historically shielded key assets like Humira from generic threats. As of 2024, AbbVie holds over 70 active patents related to immunology, providing exclusivity until at least 2029 for several products. This intellectual fortress enables premium pricing, with Humira once generating annual sales above $20 billion.

Research and development (R&D) forms another pillar, with AbbVie investing nearly $7 billion in 2023—about 13% of its revenue. This commitment drives a pipeline of over 50 clinical programs, focusing on unmet needs in oncology and neurology. For example, the approval of Venclexta for blood cancers demonstrates AbbVie's ability to leverage data-driven insights for faster market entry, outpacing competitors in certain indications.

Financially, AbbVie's balance sheet remains a strength, boasting a debt-to-equity ratio under 1.5 and consistent dividend growth. This stability supports aggressive acquisitions, such as the $63 billion purchase of Allergan in 2020, which expanded its aesthetics and neuroscience portfolios. Unlike peers facing cash flow constraints, AbbVie generates strong free cash flow, enabling reinvestment and shareholder returns. In a sector where mergers define competitive advantage, AbbVie's execution sets it apart, integrating acquired assets to boost revenue by 15% in the first year post-deal.

Strategic Insights

AbbVie's strategic roadmap emphasizes pipeline diversification and partnerships to counter patent cliffs and market saturation. With Humira's decline, the company pivots to next-generation therapies, targeting a 5-7% annual revenue growth through 2030. Key initiatives include expanding Rinvoq and Skyrizi, which together could surpass $15 billion in sales by 2025, based on current projections.

Partnerships play a critical role, as seen in AbbVie's alliance with Genmab for oncology drugs, enhancing its global reach without sole R&D burdens. This approach mitigates risks in volatile markets, such as China's regulatory environment, where AbbVie has doubled its presence since 2020. Strategically, the company addresses biosimilar threats by investing in novel mechanisms, like bispecific antibodies, to maintain leadership in immunology.

Looking ahead, AbbVie's focus on personalized medicine and digital health integration offers a competitive edge. For instance, its use of AI in clinical trials has reduced development times by 20%, per internal metrics. However, executives must navigate geopolitical tensions and supply chain disruptions, which could impact production. Compared to rivals, AbbVie's agility in adapting to these challenges—evidenced by its rapid COVID-19 response—positions it for sustained growth.

In the broader competitive landscape, AbbVie differentiates through a customer-centric model, prioritizing physician feedback to refine product launches. This has resulted in higher adoption rates for new drugs, with Rinvoq achieving market penetration 30% faster than industry averages. Business professionals should note that while AbbVie's strategies align with industry trends, its emphasis on high-margin specialties like oncology could yield returns amid rising global healthcare spending.

Conclusion

AbbVie's competitive edge in pharmaceuticals stems from its adaptive strategies and core competencies, enabling it to thrive amidst industry disruptions. By balancing innovation with financial prudence, the company not only defends its market position but also charts a path for future expansion, making it a benchmark for peers.

Key Takeaways

  • AbbVie's intellectual property and R&D investments solidify its leadership in immunology and oncology, despite patent expirations.
  • Strategic acquisitions, like Allergan, enhance portfolio diversity and drive revenue growth in emerging therapeutic areas.
  • The company's focus on partnerships and digital tools accelerates innovation, positioning it ahead of competitors in a dynamic market.
  • Financial stability supports sustained dividends and reinvestment, appealing to investors seeking long-term value.
  • AbbVie's agility in addressing global challenges underscores its potential for 5-7% annual growth through 2030.

Frequently Asked Questions

1. What factors contribute most to AbbVie's market position in immunology?
AbbVie's dominance in immunology stems from its patented biologics like Humira and newer entrants like Rinvoq, which benefit from strong clinical data and rapid FDA approvals, helping it maintain a 20% global market share.

2. How does AbbVie's patent strategy compare to its competitors?
AbbVie's extensive patent portfolio, covering over 70 assets, provides longer exclusivity periods than many rivals, such as Pfizer, allowing for higher pricing and delayed biosimilar entry.

3. What role do acquisitions play in AbbVie's growth strategy?
Acquisitions like Allergan expand AbbVie's pipelines in neuroscience and aesthetics, enabling diversification and adding billions in revenue through integrated product lines.

4. How is AbbVie addressing the challenges of biosimilar competition?
AbbVie counters biosimilars by advancing innovative therapies and forming partnerships, which have shortened development cycles and boosted new drug adoption rates.

5. What are the potential risks to AbbVie's future strategies?
Key risks include regulatory hurdles in international markets and supply chain issues, which could affect product launches and revenue projections if not managed effectively.

Sources

  1. AbbVie. (2023). Annual Report. Retrieved from AbbVie's official investor relations website.
  2. IQVIA Institute. (2024). Global Use of Medicines Report. Retrieved from IQVIA's public reports section.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.